MRC Clinical Trials Unit at University College London, 90 High Holborn, London, WC1V 6LJ, UK.
Mbale Clinical Research Institute, Pallisa Road, PO Box 291, Mbale, Uganda.
BMC Public Health. 2021 Jul 29;21(1):1480. doi: 10.1186/s12889-021-11481-6.
Severe anaemia (haemoglobin < 6 g/dL) is a leading cause of recurrent hospitalisation in African children. We investigated predictors of readmission in children hospitalised with severe anaemia in the TRACT trial (ISRCTN84086586) in order to identify potential future interventions.
Secondary analyses of the trial examined 3894 children from Uganda and Malawi surviving a hospital episode of severe anaemia. Predictors of all-cause readmission within 180 days of discharge were identified using multivariable regression with death as a competing risk. Groups of children with similar characteristics were identified using hierarchical clustering.
Of the 3894 survivors 682 (18%) were readmitted; 403 (10%) had ≥2 re-admissions over 180 days. Three main causes of readmission were identified: severe anaemia (n = 456), malaria (n = 252) and haemoglobinuria/dark urine syndrome (n = 165). Overall, factors increasing risk of readmission included HIV-infection (hazard ratio 2.48 (95% CI 1.63-3.78), p < 0.001); ≥2 hospital admissions in the preceding 12 months (1.44(1.19-1.74), p < 0.001); history of transfusion (1.48(1.13-1.93), p = 0.005); and missing ≥1 trial medication dose (proxy for care quality) (1.43 (1.21-1.69), p < 0.001). Children with uncomplicated severe anaemia (Hb 4-6 g/dL and no severity features), who never received a transfusion (per trial protocol) during the initial admission had a substantially lower risk of readmission (0.67(0.47-0.96), p = 0.04). Malaria (among children with no prior history of transfusion) (0.60(0.47-0.76), p < 0.001); younger-age (1.07 (1.03-1.10) per 1 year younger, p < 0.001) and known sickle cell disease (0.62(0.46-0.82), p = 0.001) also decreased risk of readmission. For anaemia re-admissions, gross splenomegaly and enlarged spleen increased risk by 1.73(1.23-2.44) and 1.46(1.18-1.82) respectively compared to no splenomegaly. Clustering identified four groups of children with readmission rates from 14 to 20%. The cluster with the highest readmission rate was characterised by very low haemoglobin (mean 3.6 g/dL). Sickle Cell Disease (SCD) predominated in two clusters associated with chronic repeated admissions or severe, acute presentations in largely undiagnosed SCD. The final cluster had high rates of malaria (78%), severity signs and very low platelet count, consistent with acute severe malaria.
Younger age, HIV infection and history of previous hospital admissions predicted increased risk of readmission. However, no obvious clinical factors for intervention were identified. As missing medication doses was highly predictive, attention to care related factors may be important.
ISRCTN ISRCTN84086586 .
严重贫血(血红蛋白<6g/dL)是导致非洲儿童反复住院的主要原因。我们在 TRACT 试验(ISRCTN84086586)中调查了因严重贫血住院的儿童再次入院的预测因素,以便确定潜在的未来干预措施。
对乌干达和马拉维的 3894 名幸存患儿进行了试验的二次分析。使用多变量回归分析,以死亡为竞争风险,确定出院后 180 天内所有原因再入院的预测因素。使用分层聚类识别具有相似特征的儿童组。
在 3894 名幸存者中,有 682 人(18%)再次入院;403 人(10%)在 180 天内有≥2 次再入院。再入院的主要原因有三个:严重贫血(n=456)、疟疾(n=252)和血红蛋白尿/黑尿综合征(n=165)。总的来说,增加再入院风险的因素包括 HIV 感染(风险比 2.48(95%CI 1.63-3.78),p<0.001);在前 12 个月内≥2 次住院(1.44(1.19-1.74),p<0.001);有输血史(1.48(1.13-1.93),p=0.005);漏服≥1 次试验药物(代表护理质量)(1.43(1.21-1.69),p<0.001)。无并发症的严重贫血(Hb 4-6g/dL,无严重特征)患儿,在初次入院期间从未接受输血(按试验方案),其再入院风险显著降低(0.67(0.47-0.96),p=0.04)。无输血史的疟疾(0.60(0.47-0.76),p<0.001);年龄较小(每 1 岁年龄增加 1.07(1.03-1.10),p<0.001)和已知镰状细胞病(0.62(0.46-0.82),p=0.001)也降低了再入院的风险。对于贫血再入院,巨脾和脾肿大分别使风险增加 1.73(1.23-2.44)和 1.46(1.18-1.82),与无脾肿大相比。聚类分析确定了再入院率为 14%至 20%的四个儿童组。再入院率最高的组特征为血红蛋白极低(平均 3.6g/dL)。镰状细胞病(SCD)在与慢性反复住院或主要未确诊 SCD 严重急性发作相关的两个聚类中占主导地位。最后一个聚类疟疾发生率很高(78%)、有严重体征和血小板计数非常低,与急性严重疟疾一致。
年龄较小、HIV 感染和既往住院史预测再入院风险增加。然而,没有发现明显的干预临床因素。由于漏服药物的预测性很高,因此关注护理相关因素可能很重要。
ISRCTN ISRCTN84086586。